Vidac has built a portfolio of product candidates that address significant unmet medical needs. The value proposition of these novel drugs stems from a unique mechanism of action that offers dermatologists, oncologists and patients both efficacy as well as tolerability.

First-in-Class Portfolio in Dermatology and Oncology

image/svg+xml Program Indication Discovery Preclinical POC Phase 1 Phase 2 Phase 3 Dermatology VDA-1102 ointment VDA-1102 ointment SELECTIVE TARGETING OF CANCER CELLS 2019 Actinic Keratosis CTCL Oncology VDA-1102 VDA-1275 Injection Solid Tumors Solid Tumors IMMUNO-METABOLICS Completed Vidac Pharma for non skin cancer applications VDA 1275 might be developed as a spin off of 2020 Completed Ongoing 2023 2021-